VX1 fundamentals
An in-depth look to VERTEX PHARMAC. DL-,01 operating, investing, and financing activities
VX1 free cash flow for Q3 24 is 1.17 B EUR. For 2023, VX1 free cash flow was 3.02 B EUR and operating cash flow was 3.2 B EUR.
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM